Literature DB >> 2809620

Normal muscle CPT1 and CPT2 activities in hepatic presentation patients with CPT1 deficiency in fibroblasts. Tissue specific isoforms of CPT1?

I Tein1, F Demaugre, J P Bonnefont, J M Saudubray.   

Abstract

Human carnitine palmitoyltransferase (CPT) deficiency results in 2 clinical forms: a more common "muscular form" with myoglobinuria with or without delayed or impaired ketogenesis and a rare "hepatic form" with hypoketotic hypoglycemia, encephalopathy and seizures without muscular manifestations. We present 2 patients, a male (patient 1) and a female (patient 2) with infantile "hepatic" CPT deficiency and previously documented CPT1 deficiency in fibroblasts. In patient 2, a deficiency of "total" CPT activity in liver had also been previously documented. We set up an isotope exchange assay system that effectively differentiated CPT1 and CPT2 activities in muscle. We found normal CPT1 and CPT2 activities in our patients under near saturating substrate conditions. The CPT1 and CPT2 activities were suppressed to a strikingly similar degree under different kinetic conditions as compared to control muscle and were found to have similar Km values for carnitine and PCoA. With Km concentrations of carnitine, the mean residual activities of CPT1 for patients 1 and 2 were 49 and 44%, respectively (control range 40-53%); the mean residual activities of CPT2 were 60 and 46%, respectively (control range 49-59%). With Km concentrations of PCoA, the mean residual activities of CPT1 for patients 1 and 2 were 52 and 58%, respectively (control range of 52-59%); mean residual activities of CPT2 were 54% and 56%, respectively (control range of 51-68%). When the Vmax concentration of PCoA was doubled and bovine serum albumin reduced to 0.1%, the mean residual activities of CPT1 for patients 1 and 2 were 69 and 63%, respectively (control range 60-80%). In "muscular" patients, a marked absolute deficiency of CPT2 activity (less than 12% residual) was found with an apparent increased sensitivity to suppression of enzymatic activity when the Km concentration of carnitine was used. We suggest that CPT1 and CPT2 may be separate proteins. Furthermore, CPT1 itself may exist as tissue-specific isoforms being the same protein in liver and fibroblasts and a different protein in muscle. Either could be encoded for by the same or closely related genes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809620     DOI: 10.1016/0022-510x(89)90139-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.

Authors:  Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

Review 2.  Defects in activation and transport of fatty acids.

Authors:  M Brivet; A Boutron; A Slama; C Costa; L Thuillier; F Demaugre; D Rabier; J M Saudubray; J P Bonnefont
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 3.  Mammalian mitochondrial beta-oxidation.

Authors:  S Eaton; K Bartlett; M Pourfarzam
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

4.  Features of carnitine palmitoyltransferase type I deficiency.

Authors:  S E Olpin; J Allen; J R Bonham; S Clark; P T Clayton; J Calvin; M Downing; K Ives; S Jones; N J Manning; R J Pollitt; S J Standing; M S Tanner
Journal:  J Inherit Metab Dis       Date:  2001-02       Impact factor: 4.982

5.  Carnitine palmitoyltransferase I deficiency in neonate identified by dried blood spot free carnitine and acylcarnitine profile.

Authors:  K G Sim; V Wiley; K Carpenter; B Wilcken
Journal:  J Inherit Metab Dis       Date:  2001-02       Impact factor: 4.982

Review 6.  Carnitine palmitoyl transferase I deficiency presenting as a Reye-like syndrome without hypoglycaemia.

Authors:  C Vianey-Saban; B Mousson; C Bertrand; D Stamm; R Dumoulin; M T Zabot; P Divry; D Floret; M Mathieu
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

7.  Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene.

Authors:  C H Britton; R A Schultz; B Zhang; V Esser; D W Foster; J D McGarry
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

Review 8.  Disorders of mitochondrial long-chain fatty acid oxidation.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

9.  Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies.

Authors:  F Demaugre; J P Bonnefont; M Colonna; C Cepanec; J P Leroux; J M Saudubray
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  Loss of C2orf69 defines a fatal autoinflammatory syndrome in humans and zebrafish that evokes a glycogen-storage-associated mitochondriopathy.

Authors:  Hui Hui Wong; Sze Hwee Seet; Michael Maier; Ayse Gurel; Ricardo Moreno Traspas; Cheryl Lee; Shan Zhang; Beril Talim; Abigail Y T Loh; Crystal Y Chia; Tze Shin Teoh; Danielle Sng; Jarred Rensvold; Sule Unal; Evgenia Shishkova; Ece Cepni; Fatima M Nathan; Fernanda L Sirota; Chao Liang; Nese Yarali; Pelin O Simsek-Kiper; Tadahiro Mitani; Serdar Ceylaner; Ozlem Arman-Bilir; Hamdi Mbarek; Fatma Gumruk; Stephanie Efthymiou; Deniz Uğurlu Çi Men; Danai Georgiadou; Kortessa Sotiropoulou; Henry Houlden; Franziska Paul; Davut Pehlivan; Candice Lainé; Guoliang Chai; Nur Ain Ali; Siew Chin Choo; Soh Sok Keng; Bertrand Boisson; Elanur Yılmaz; Shifeng Xue; Joshua J Coon; Thanh Thao Nguyen Ly; Naser Gilani; Dana Hasbini; Hulya Kayserili; Maha S Zaki; Robert J Isfort; Natalia Ordonez; Kornelia Tripolszki; Peter Bauer; Nima Rezaei; Simin Seyedpour; Ghamar Taj Khotaei; Charles C Bascom; Reza Maroofian; Myriam Chaabouni; Afaf Alsubhi; Wafaa Eyaid; Sedat Işıkay; Joseph G Gleeson; James R Lupski; Jean-Laurent Casanova; David J Pagliarini; Nurten A Akarsu; Sebastian Maurer-Stroh; Arda Cetinkaya; Aida Bertoli-Avella; Ajay S Mathuru; Lena Ho; Frederic A Bard; Bruno Reversade
Journal:  Am J Hum Genet       Date:  2021-05-25       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.